Tarlatamab is a targeted therapeutic drug primarily indicated for the clinical treatment of specific types of cancer. Its common side effects include pyrexia, cytokine release syndrome, fatigue, decreased appetite, and others. In severe instances, it may trigger immune-related adverse reactions (e.g., pneumonia, liver injury) or neurological symptoms. It is imperative to administer the medication strictly in accordance with a doctor’s instructions and carry out timely monitoring throughout treatment.
I. Common Side Effects
Pyrexia
Approximately 30% to 50% of patients may experience low-to-moderate fever, which is often accompanied by chills or asthenia.
Cytokine Release Syndrome (CRS)
Manifested as high fever, hypotension, or dyspnea, this condition mostly occurs during the initial phase of medication administration and requires close observation.
Gastrointestinal reactions
Including nausea, diarrhea, and constipation. Most reactions are mild in severity and can be alleviated through dietary adjustments or symptomatic medications.
Fatigue
A persistent sense of weakness is relatively common. Patients are advised to arrange rest and physical activities reasonably.
II. Severe Side Effects Requiring Vigilance
Immune-Related Adverse Reactions
Pneumonia: Immediate medical attention is required if symptoms such as cough and dyspnea occur.
Liver injury: Presented as jaundice and elevated transaminase levels; regular liver function testing is necessary.
Other Severe Adverse Reactions
Neurological symptoms: Such as headache and vertigo. Severe cases may involve neurotoxic reactions (e.g., confusion).
Cardiac disorders: Rare but potentially associated with arrhythmia or myocarditis, necessitating electrocardiogram monitoring.
III. Precautions for Medication Use
Dose adjustment as prescribed by a doctor
Depending on the severity of side effects, the physician may decide to suspend treatment, reduce the dosage, or discontinue the medication entirely.
Regular monitoring
Complete blood count, liver and kidney function, as well as cardiopulmonary function should be examined every 2 to 4 weeks during the course of treatment.
Signs for prompt medical consultation
Seek immediate medical care in the event of persistent high fever (>39°C), severe dyspnea, chest pain, skin jaundice, or altered consciousness.
Contraindications and populations for cautious use: Patients with active infections or severe cardiopulmonary diseases require a careful risk assessment before use; the drug is contraindicated in pregnant and lactating women.
IV. Patient Management Recommendations
Record symptom changes
Document body temperature, physical performance status, and any abnormal reactions on a daily basis, and provide detailed information during follow-up visits.
Reduce infection risk
Pay attention to personal hygiene and avoid crowded public places.
Diet and hydration
Adopt a small-meal, frequent-feeding regimen and ensure adequate water intake to alleviate the burden on the digestive tract.
Tarlatamab is a prescription drug that must be used under the guidance of an oncologist. Before treatment initiation, a thorough assessment of the patient’s underlying diseases and medication-related risks is required. During treatment, multidisciplinary collaboration should be implemented to manage side effects effectively.
